Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

44.65
+0.55001.25%
Post-market: 44.64-0.0100-0.02%19:00 EST
Volume:3.54M
Turnover:157.79M
Market Cap:26.04B
PE:25.49
High:44.93
Open:44.31
Low:43.95
Close:44.10
52wk High:44.93
52wk Low:29.66
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.81
T/O Rate:0.93%
Dividend:0.87
Dividend Rate:1.95%
EPS(TTM):1.75
EPS(LYR):1.92
ROE:13.11%
ROA:5.22%
PB:4.06
PE(LYR):23.30

Loading ...

Royalty Pharma CFO Terrance P. Coyne Reports Disposal of Common Shares

Reuters
·
Feb 05

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Feb 03

Royalty Pharma Shares Rise After UBS Upgrade

MT Newswires Live
·
Jan 31

UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38

MT Newswires Live
·
Jan 31

Assessing Royalty Pharma (RPRX) Valuation After Teva Autoimmune Funding Partnership Attracts Fresh Attention

Simply Wall St.
·
Jan 29

Royalty Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
Jan 27

Royalty Pharma EVP Marshall Urist Reports Disposal of Common Shares

Reuters
·
Jan 27

EVP Marshall Urist Reports Disposal of Royalty Pharma plc Common Shares

Reuters
·
Jan 21

Royalty Pharma plc to Announce Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Jan 21

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Jan 14

Royalty Pharma provides update on business performance

TIPRANKS
·
Jan 12

Royalty Pharma Targets 14%-16% Top-Line Growth for 2025

Reuters
·
Jan 12

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 12

Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408

TIPRANKS
·
Jan 12

BRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo

Reuters
·
Jan 12

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

THOMSON REUTERS
·
Jan 12

Teva - Teva to Share Tev-'408 Trial Results in 2026

THOMSON REUTERS
·
Jan 12

Royalty Pharma - to Provide up to $500 Mln for Teva's Tev-'408

THOMSON REUTERS
·
Jan 12

Royalty Pharma : Tev-'408 Is Currently in Phase 1B for Treatment of Vitiligo and in Phase 2a for Celiac Disease

THOMSON REUTERS
·
Jan 12

Teva and Royalty Pharma Partner in $500 Million Deal to Advance TEV-'408 for Vitiligo

Reuters
·
Jan 12